Precision biosciences announces grant of inducement awards under nasdaq listing rule 5635(c)(4)

Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), an advanced gene editing company utilizing its novel proprietary arcus® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that, on september 18, 2024, the compensation committee of precision's board of directors approved the grant of inducement awards to new employees under the precision biosciences, inc. 2021 em.
NDAQ Ratings Summary
NDAQ Quant Ranking